Glass House Brands (GLAS) Asset Utilization Ratio (2021 - 2026)

Glass House Brands (GLAS) posted quarterly Asset Utilization Ratio of 0.55 for Q1 2026, down 7.82% quarter-over-quarter from 0.6 in Q4 2025.

Glass House Brands (GLAS) Asset Utilization Ratio (2021 - 2026) Analysis & Trends

Glass House Brands (GLAS) has reported Asset Utilization Ratio for 6 consecutive years, with 0.55 the latest figure, recorded in Q1 2026.

In Q1 2026, Asset Utilization Ratio changed N/A year-over-year to 0.55; the TTM figure through Mar 2026 stood at 0.55 (changed N/A YoY), while the FY2025 annual figure was 0.58, down 11.54% from the prior year.
Asset Utilization Ratio eased to 0.55 in Q1 2026 per GLAS's latest filing, from 0.6 in the prior quarter.
Across five years, Asset Utilization Ratio topped out at 131679294429.43 in Q1 2022 and bottomed at 0.25 in Q4 2022.
Historically, Asset Utilization Ratio has averaged 25085370279.18 across 5 years, with a median of 0.59 in 2025.
On a YoY basis, Asset Utilization Ratio climbed as much as 148702223834213.72% in 2022 and fell as far as 100.0% in 2022.
Glass House Brands' Asset Utilization Ratio stood at 0.25 in 2022, then jumped by 45.18% to 0.37 in 2023, then surged by 41.93% to 0.52 in 2024, then climbed by 14.76% to 0.6 in 2025, then decreased by 7.82% to 0.55 in 2026.
Business Quant data shows GLAS's Asset Utilization Ratio at 0.55 in Q1 2026, 0.6 in Q4 2025, and 0.6 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn	0.43
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn	0.63
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn	0.47
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn	0.45
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn	0.41
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn	0.66
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn	0.37
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-	-
10	Glass House Brands	837.25 Mn	818.69 Mn	15.77 Mn	0.48

Download Data